Nordhealth AS (OSL:NORDH)
22.20
0.00 (0.00%)
Jul 14, 2026, 4:25 PM CET
Nordhealth AS Revenue
Nordhealth AS had revenue of 13.47M EUR in the quarter ending March 31, 2026, with 7.92% growth. This brings the company's revenue in the last twelve months to 51.83M, up 7.95% year-over-year. In the year 2025, Nordhealth AS had annual revenue of 50.84M with 11.31% growth.
Revenue (ttm)
51.83M EUR
Revenue Growth
+7.95%
P/S Ratio
3.01
Revenue / Employee
113.41K EUR
Employees
457
Market Cap
1.75B NOK
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.84M | 5.17M | 11.31% |
| Dec 31, 2024 | 45.68M | 8.85M | 24.03% |
| Dec 31, 2023 | 36.83M | 5.78M | 18.60% |
| Dec 31, 2022 | 31.05M | 10.75M | 52.96% |
| Dec 31, 2021 | 20.30M | 7.62M | 60.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 719.89M |
| Photocure ASA | 671.85M |
| Omda AS | 493.60M |
| Vistin Pharma ASA | 449.47M |
| ArcticZymes Technologies ASA | 128.37M |
| Nykode Therapeutics AS | 5.42M |
| Thor Medical ASA | 839.00K |
| Lytix Biopharma ASA | 377.00K |
Nordhealth AS News
- 2 months ago - Nordhealth AS Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Nordhealth AS Slides: Q1 2026 - Filings
- 4 months ago - Nordhealth AS Earnings Call Transcript: Q4 2025 - Transcripts
- 4 months ago - Nordhealth AS Annual report: Q4 2025 - Filings
- 4 months ago - Nordhealth AS Slides: Q4 2025 - Filings
- 8 months ago - Nordhealth AS Earnings Call Transcript: Q3 2025 - Transcripts
- 8 months ago - Nordhealth AS Slides: Q3 2025 - Filings
- 11 months ago - Nordhealth AS Earnings Call Transcript: Q2 2025 - Transcripts